Company intelligence / Profile preview

Daavlin

Bryan, Ohio, United States

Ownership: Private
Employees: ~85
Development stage: Other

Overview

Daavlin's phototherapeutic devices are used worldwide both in clinical and home settings for photoresponsive skin disorders; their technology is integrated into clinical routines and has supported pivotal studies of narrowband UVB therapy. The company's companion device for SGX301 is awaiting further regulatory progress based on the drug's development.

Therapeutic areas: OncologyDermatology
Modalities: DeviceNon-pharmacological therapy
Industry: Therapeutic Medical Devices

Partnerships

Soligenix (exclusive device supply/distribution for SGX301)National Psoriasis FoundationVitiligo Support InternationalAmerican Academy of Dermatology

Beyond the preview

Go deeper on Daavlin.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Daavlin.

Explore the full profile